Genprex Inc (GNPX)

[swanlinbar]

GNPX-Genprex Signs Agreement With Aldevron To Supply RUSC2 Tumor Suppressor Candidate Plasmid DNA For Use In Genprex's Clinical Development Program Evaluating Its Oncoprex For Lung Cancer
8:03 am ET September 27, 2018 (Benzinga) Print
Newly manufactured plasmids will be applied in clinical trials evaluating Oncoprex™ in combination with targeted therapies and immunotherapies
AUSTIN, Texas & CAMBRIDGE, Mass. & FARGO, N.D.--(BUSINESS WIRE)-- Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has signed an agreement with Aldevron, a leading contract manufacturing organization, to supply TUSC2 (Tumor Suppressor Candidate2) plasmid DNA for use in Genprex’s clinical development program evaluating its immunogene therapy Oncoprex™ for the treatment of non-small cell lung cancer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180927005155/en/
“Plasmid DNA plays an important role in the delivery of gene therapies into target cells,” said Rodney Varner, Chairman and Chief Executive Officer of Genprex. “Aldevron is a leading plasmid manufacturer that offers world-class laboratory and manufacturing programs. Through this agreement, we have established a GMP-validated supply of plasmid DNA vectors for our expanding clinical program evaluating the utility of Oncoprex in combination with some of the most promising new therapies for cancer.”
“Aldevron is honored to partner with Genprex in the development of Oncoprex,” said Michael Chambers, CEO of Aldevron. “This collaboration furthers our goal to provide high-quality plasmid DNA and other biologics to leading companies such as Genprex that are creating treatments that could have a significant impact on human health.”

© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Earnings Calendar and Events Data provided by |Terms of Use| © 2018 Wall Street Horizon, Inc.

Market data and information provided by Morningstar.